Arecor Therapeutics plc
("Arecor" or the "Company")

Arecor to present at Oppenheimer Annual Healthcare MedTech & Services Conference

Cambridge, UK, 9 March 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, will be presenting at the Oppenheimer 36^th Annual Healthcare MedTech and Services Conference on 16 March. The Arecor team will also be attending the Advanced Technologies & Treatments for Diabetes (ATTD) conference, from 11-14 March. Full details for both events are below:

Oppenheimer 36th Annual Healthcare MedTech & Services Conference - 16-19 March 2026, online

Sarah Howell will be presenting on Arecor's lead programme AT278, the only ultra-concentrated, ultra-rapid acting insulin, designed to lower patient burden and improve outcomes for people with diabetes in combination with Automated Insulin Delivery (AID) Systems, at the Oppenheimer conference on March 16, 2026 at 9.20am EDT. Click here to register to watch the presentation.  The presentation will also be made available on Arecor's website here after the event. David Ellam, CFO, will also be attending.

Advanced Technologies & Treatments for Diabetes (ATTD) - 11-14 March 2026, Barcelona

Sarah Howell (CEO), Jan Jezek (CSO) and David Gerring (CDO) will also be attending ATTD 2026. The conference brings clinicians, diabetes care providers, researchers, industry, investors, reimbursement authorities, and regulators together in order to collaborate to drive rapid progress in diabetes care.

For attendees at either conference interested in meeting the Arecor team, please email [email protected].

-ENDS-

For more information, please contact:

Notes to Editors

About Arecor

Arecor Therapeutics plc is a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin, which enables disruptive drug delivery devices. It is being co-developed with Sequel Med Tech, a company commercialising state-of-the art insulin delivery devices. Arecor is also developing a novel oral delivery platform for peptides with its first validation target a GLP-1 receptor agonist.

The Company is quoted on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com

About AT278

AT278 is a novel proprietary formulation of an existing insulin, designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). With its best-in-class profile, it has the potential to disrupt the market for insulin treatment as the first concentrated, yet very rapid acting insulin for the growing population of people with diabetes with high daily insulin needs as well as to act as a critical enabler in the development of next-generation, miniaturised longer wear automated insulin delivery (AID) systems.